Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2015, Article ID 108179, 15 pages
http://dx.doi.org/10.1155/2015/108179
Research Article

Pentoxifylline Neuroprotective Effects Are Possibly Related to Its Anti-Inflammatory and TNF-Alpha Inhibitory Properties, in the 6-OHDA Model of Parkinson’s Disease

1Faculty of Medicine of the Federal University of Ceará, Rua Coronel Nunes de Melo 1127, 60430-270 Fortaleza, CE, Brazil
2Faculty of Medicine Estácio of Juazeiro do Norte, Avenida Tenente Raimundo Rocha 515, 63048-080 Juazeiro do Norte, CE, Brazil

Received 2 May 2015; Revised 20 August 2015; Accepted 27 August 2015

Academic Editor: Ivan Bodis-Wollner

Copyright © 2015 Kelly Rose Tavares Neves et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Kreth, C. Ledderose, B. Luchting, F. Weis, and M. Thiel, “Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways,” Shock, vol. 34, no. 1, pp. 10–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Mogi, M. Harada, P. Riederer, H. Narabayashi, K. Fujita, and T. Nagatsu, “Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients,” Neuroscience Letters, vol. 165, no. 1-2, pp. 208–210, 1994. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Baratz, D. Tweedie, J.-Y. Wang et al., “Transiently lowering tumor necrosis factor-alpha synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice,” Journal of Neuroinflammation, vol. 12, article 45, 2015. View at Publisher · View at Google Scholar
  4. K. R. Chaudhuri and A. H. Schapira, “Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment,” The Lancet Neurology, vol. 8, no. 5, pp. 464–474, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. Y.-Y. Xu, S.-H. Kuo, Z. Liang et al., “The natural history of depression in Parkinson’s disease within 30-month follow up,” Parkinson's Disease, vol. 2015, Article ID 362892, 7 pages, 2015. View at Publisher · View at Google Scholar
  6. J. A. Machado-Filho, A. O. Correia, A. B. A. Montenegro et al., “Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions,” Behavioural Brain Research, vol. 264, pp. 116–125, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. O. M. E. Abdel-Salam, A. R. Baiuomy, S. M. El-Shenawy, and M. S. Arbid, “The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat,” Pharmacological Research, vol. 47, no. 4, pp. 331–340, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Bollen and J. Prickaerts, “Phosphodiesterases in neurodegenerative disorders,” IUBMB Life, vol. 64, no. 12, pp. 965–970, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Beshay, F. Croze, and G. J. Prud'homme, “The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo,” Clinical Immunology, vol. 98, no. 2, pp. 272–279, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. M. C. Leal, J. C. Casabona, M. Puntel, and F. Pitossi, “Interleukin-1beta and TNF-alpha: reliable targets for protective therapies in Parkinson's disease?” Frontiers in Cellular Neuroscience, vol. 7, article 53, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. R. D. B. Bruno, T. F. Marques, T. M. T. Batista et al., “Pentoxifylline treatment improves neurological and neurochemical deficits in rats subjected to transient brain ischemia,” Brain Research, vol. 1260, pp. 55–64, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Olmos and J. Lladó, “Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity,” Mediators of Inflammation, vol. 2014, Article ID 861231, 12 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. L. C. Schmued and K. J. Hopkins, “Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration,” Brain Research, vol. 874, no. 2, pp. 123–130, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. J. G. Nutt, J. H. Carter, and G. J. Sexton, “The dopamine transporter: importance in Parkinson's disease,” Annals of Neurology, vol. 55, no. 6, pp. 766–773, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. R. M. De Pablos, A. J. Herrera, A. M. Espinosa-Oliva et al., “Chronic stress enhances microglia activation and exacerbates death of nigral dopaminergic neurons under conditions of inflammation,” Journal of Neuroinflammation, vol. 11, article 34, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. S. K. Muchhala and K. E. Benzeroual, “Pentoxifylline suppressed LPS-induced inflammatory and apoptotic signaling in neuronal cells,” Advances in Bioscience and Biotechnology, vol. 3, no. 6, pp. 731–739, 2012. View at Publisher · View at Google Scholar
  17. S. Hunot and E. C. Hirsch, “Neuroinflammatory processes in Parkinson's disease,” Annals of Neurology, vol. 53, supplement 3, pp. S49–S60, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Halliday, K. Murphy, and H. Cartwright, “Pathology of Parkinson's disease,” in Parkinson's Disease and Other Movement Disorders, E. Wolters and C. Baumann, Eds., Vu University Press, Amsterdam, The Netherlands, 2014. View at Google Scholar
  19. S. E. Seidi and J. A. Potashkin, “The promise of neuroprotective agents in Parkinson's disease,” Frontiers in Neurology, vol. 2, article 68, 2011. View at Publisher · View at Google Scholar
  20. N. Exner, A. K. Lutz, C. Haass, and K. F. Winklhofer, “Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences,” The EMBO Journal, vol. 31, no. 14, pp. 3038–3062, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. T. M. Bah, S. Kaloustian, G. Rousseau, and R. Godbout, “Pretreatment with pentoxifylline has antidepressant-like effects in a rat model of acute myocardial infarction,” Behavioural Pharmacology, vol. 22, no. 8, pp. 779–784, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Menza, R. D. Dobkin, H. Marin, and K. Bienfait, “Sleep disturbances in Parkinson's disease,” Movement Disorders, vol. 25, no. 1, pp. S117–S122, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Greener, “Managing the double burden of depression and Parkinson's disease,” Progress in Neurology and Psychiatry, vol. 16, no. 3, pp. 16–17, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. J.-F. Chen, P. K. Sonsalla, F. Pedata et al., “Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and ‘fine tuning’ modulation,” Progress in Neurobiology, vol. 83, no. 5, pp. 310–331, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. C. L. Raison, R. E. Rutherford, B. J. Woolwine et al., “A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers,” Archives of General Psychiatry, vol. 70, no. 1, pp. 31–41, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Lotharius and P. Brundin, “Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein,” Nature Rreviews. Neuroscience, vol. 3, pp. 932–942, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. M. P. Mattson, W. A. Pedersen, W. Duan, C. Culmsee, and S. Camandola, “Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases,” Annals of the New York Academy of Sciences, vol. 893, pp. 154–175, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Zhu, J. Zhang, and Y. Zeng, “Overview of tyrosine hydroxylase in Parkinson's disease,” CNS and Neurological Disorders—Drug Targets, vol. 11, no. 4, pp. 350–358, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Tabrez, N. R. Jabir, S. Shakil et al., “A synopsis on the role of tyrosine hydroxylase in Parkinson's disease,” CNS & Neurological Disorders Drug Targets, vol. 11, no. 4, pp. 395–409, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. V. Sossi, R. de la Fuente-Fernández, M. Schulzer, A. R. Troiano, T. J. Ruth, and A. J. Stoessl, “Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study,” Annals of Neurology, vol. 62, no. 5, pp. 468–474, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. S. D. Skaper, P. Giusti, and L. Facci, “Microglia and mast cells: two tracks on the road to neuroinflammation,” The FASEB Journal, vol. 26, no. 8, pp. 3103–3117, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. W.-D. Le, D. Rowe, W. Xie, I. Ortiz, Y. He, and S. H. Appel, “Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease,” Journal of Neuroscience, vol. 21, no. 21, pp. 8447–8455, 2001. View at Google Scholar · View at Scopus
  33. L. Qian and P. M. Flood, “Microglial cells and Parkinson's disease,” Immunologic Research, vol. 41, no. 3, pp. 155–164, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. V. H. Perry, “Innate inflammation in Parkinson’s disease,” Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 9, 2012. View at Publisher · View at Google Scholar
  35. C. Cunningham, “Microglia and neurodegeneration: the role of systemic inflammation,” Glia, vol. 61, no. 1, pp. 71–90, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. V. H. Perry and C. Holmes, “Microglial priming in neurodegenerative disease,” Nature Reviews Neurology, vol. 10, no. 4, pp. 217–224, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. M. T. Tebano, A. Pintor, C. Frank et al., “Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum,” Journal of Neuroscience Research, vol. 77, no. 1, pp. 100–107, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Saura, E. Angulo, A. Ejarque et al., “Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia,” Journal of Neurochemistry, vol. 95, no. 4, pp. 919–929, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. A. D. Wahner, J. M. Bronstein, Y. M. Bordelon, and B. Ritz, “Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease,” Neurology, vol. 69, no. 19, pp. 1836–1842, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Sawada, K. Imamura, and T. Nagatsu, “Role of cytokines in inflammatory process in Parkinson's disease,” in Parkinson's Disease and Related Disorders, vol. 70 of Journal of Neural Transmission. Supplementa, pp. 373–381, Springer, Vienna, Austria, 2006. View at Publisher · View at Google Scholar
  41. D. Lindqvist, S. Hall, Y. Surova et al., “Cerebrospinal fluid inflammatory markers in Parkinson's disease—associations with depression, fatigue, and cognitive impairment,” Brain, Behavior, and Immunity, vol. 33, pp. 183–189, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. A. L. Bartels and K. L. Leenders, “Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration,” Current Neuropharmacology, vol. 8, no. 1, pp. 62–68, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. G. S. Viana, F. A. O. Garcia, S. Pinto et al., “Pentoxifylline, a phosphodiesterase inhibitor decreases hyperglycemia. Glycated hemoglobin and iNOS expression in diabetic rats,” Journal of Diabetes, vol. 5, pp. 37–38, 2013, Proceedings of the 5th International Congress on Prediabetes and the Metabolic Syndrome, Vienna, Austria. View at Google Scholar
  44. V. B. Bhat and K. M. Madyastha, “Antioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs pentoxifylline and lisofylline,” Biochemical and Biophysical Research Communications, vol. 288, no. 5, pp. 1212–1217, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Sandoval, J. Escobar, J. Pereda et al., “Pentoxifylline prevents loss of PP2A phosphatase activity and recruitment of histone acetyltransferases to proinflammatory genes in acute pancreatitis,” The Journal of Pharmacology & Experimental Therapeutics, vol. 331, no. 2, pp. 609–617, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. J. C. M. Ximenes, K. R. T. Neves, L. K. A. M. Leal et al., “Valproic acid neuroprotection in the 6-OHDA model of Parkinson’s disease is possibly related to its anti-inflammatory and HDAC inhibitory properties,” Journal of Neurodegenerative Diseases, vol. 2015, Article ID 313702, 14 pages, 2015. View at Publisher · View at Google Scholar
  47. P. Hickey and M. Stacy, “Adenosine A2A antagonists in Parkinson's disease: what's next?” Current Neurology and Neuroscience Reports, vol. 12, no. 4, pp. 376–385, 2012. View at Publisher · View at Google Scholar · View at Scopus